Eledon Pharmaceuticals (ELDN) Shares Outstanding (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Shares Outstanding (Entity) data on file, last reported at $112.4 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 45.77% year-over-year to $112.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.4 million (up 45.77% YoY) and the FY2025 annual result came in at $75.4 million, up 55.39% from the prior year.
• Shares Outstanding (Entity) advanced to $112.4 million in Q1 2026, from $75.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $112.4 million in Q1 2026 to a low of $13.8 million in Q1 2022.
• A 5-year average of $42.9 million and a median of $30.0 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) declined 3.84% — and 2025, when it jumped 210.83%.
• Tracing ELDN's Shares Outstanding (Entity) over 5 years: stood at $13.8 million in 2022, then soared by 75.75% to $24.2 million in 2023, then surged by 100.49% to $48.5 million in 2024, then soared by 55.39% to $75.4 million in 2025, then soared by 49.04% to $112.4 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $112.4 million (Q1 2026), $75.4 million (Q4 2025), and $77.2 million (Q3 2025), per Business Quant data.